The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes
Abstract
Objective : Low levels of testosterone in men have been shown to be associated with type 2 diabetes, visceral adiposity, dyslipidaemia and metabolic syndrome. We investigated the effect of testosterone treatment on insulin resistance and glycaemic control in hypogonadal men with type 2 diabetes. Design : This was a double-blind placebo-controlled crossover study in 24 hypogonadal men (10 treated with insulin) over the age of 30 years with type 2 diabetes. Methods : Patients were treated with i.m. testosterone 200 mg every 2 weeks or placebo for 3 months in random order, followed by a washout period of 1 month before the alternate treatment phase. The primary outcomes were changes in fasting insulin sensitivity (as measured by homeostatic model index (HOMA) in those not on insulin), fasting blood glucose and glycated haemoglobin. The secondary outcomes were changes in body composition, fasting lipids and blood pressure. Statistical analysis was performed on the delta values, with the treatment effect of placebo compared against the treatment effect of testosterone. Results : Testosterone therapy reduced the HOMA index (−1.73 ± 0.67, P = 0.02, n = 14), indicating an improved fasting insulin sensitivity. Glycated haemoglobin was also reduced (−0.37 ± 0.17%, P = 0.03), as was the fasting blood glucose (−1.58 ± 0.68 mmol/l, P = 0.03). Testosterone treatment resulted in a reduction in visceral adiposity as assessed by waist circumference (−1.63 ± 0.71 cm, P = 0.03) and waist/hip ratio (−0.03 ± 0.01, P = 0.01). Total cholesterol decreased with testosterone therapy (−0.4 ± 0.17 mmol/l, P = 0.03) but no effect on blood pressure was observed. Conclusions : Testosterone replacement therapy reduces insulin resistance and improves glycaemic control in hypogonadal men with type 2 diabetes. Improvements in glycaemic control, insulin resistance, cholesterol and visceral adiposity together represent an overall reduction in cardiovascular risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin sensitivity may improve within few days, but effects on glycemic control become evident only after 3–12 months.”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“and a decrease in the waist hip ratio after 3 months (31, 36) or after 6 months and 30 weeks respectively (17).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decrease in trunk fat or waist circumference was noted in a number of studies after 3 months (35, 36) with continuous decline over 24 months (32)”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“Several studies indicate that upon testosterone administration, serum glucose is reduced after 3 months in men with impaired glucose tolerance (31, 36, 43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decline in HbA1c was observed after 3 months (31, 36, 43) with further decrease after 12 months (43).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“A decrease in serum proinsulin and insulin was noted after 3 months (43) or 6 months (45), and a decrease in homeostasis model assessment index of insulin resistance (HOMA-IR) after 3 months (36) or 6 months (45–47).”
From Onset of effects of testosterone treatment and time span until maximum effects are achieved (2011) · cites this paper as [36]
In the citing paper
“Certainly, testosterone replacement can improve performance, mood, and libido in men with hypogonadism (22) and augments insulin sensitivity (11,15).”
From Low testosterone levels are common and associated with insulin resistance in men with diabetes (2008) · cites this paper as [11]
In the citing paper
“T plays an important role in maintaining glycemic control [2].”
In the citing paper
“Furthermore, there is recent evidence that testosterone replacement therapy improves insulin resistance, glycemic control, cholesterol levels, and waist circumference in diabetic men with low testosterone levels (26).”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
In the citing paper
“Testosterone treatment has also been shown to reduce insulin resistance in obese men (23,24), men with heart failure (25), and type 2 diabetic subjects (26).”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
In the citing paper
“Two studies in type 2 diabetic men have shown an improvement in glycemic control (26,27) with testosterone replacement therapy”
From Clinical and Biochemical Assessment of Hypogonadism in Men With Type 2 Diabetes (2007) · cites this paper as [26]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031069 · Cited by 731
Self-citationThe assessment of insulin resistance in man
Wallace, T. M., & Matthews, D. R. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00745.x · Cited by 685
Validation of a screening questionnaire for androgen deficiency in aging males
Morley, J. E., Charlton, E., Patrick, P., Kaiser, F. E., Cadeau, P., McCready, D., & Perry, H. M. (2000) · Metabolism · doi:10.1053/meta.2000.8625 · Cited by 662
(1996) · PubMed · Cited by 643
Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes
Dhindsa, S., Prabhakar, S., Sethi, M., Bandyopadhyay, A., Chaudhuri, A., & Dandona, P. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0804 · Cited by 631
Stellato, R. K., Feldman, H. A., Hamdy, O., Horton, E. S., & McKinlay, J. B. (2000) · Diabetes Care · doi:10.2337/diacare.23.4.490 · Cited by 618
Oh, J.-Y., Barrett-Connor, E., Wedick, N. M., & Wingard, D. L. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.55 · Cited by 594
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–700 of 785
Testosterone and the Metabolic Syndrome in Men: Current Knowledge
Nieschlag, E., & Zitzmann, M. (2006) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 3
Ho, C., Yu, H., Wang, C., Jaw, F., Hsieh, J., Liao, W.-C., Pu, Y., & Liu, S. (2013) · PLoS ONE · doi:10.1371/annotation/c226aa64-8d3b-4c29-971b-84f87b618291 · Cited by 4
Effects of testosterone deficiency and therapy on the cardiometabolic syndrome in men
Saad, F., & Traish, A. M. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.08.004 · Cited by 2
Clinical Benefits of Testosterone Replacement Therapy in Men: Evidence from A Narrative Review
Quintero, M. F. A. (2025) · International Journal of Medical Science and Clinical Research Studies · doi:10.47191/ijmscrs/v5-i09-14 · Cited by 2
Xu, H., Zhang, H., Yang, R., Xie, X., Cao, Z., Zhao, Y. (., Lin, H., Lu, D., Bischoff, F. Z., Zhang, X., et al. (2026) · The Innovation Nutrition · doi:10.59717/j.xinn-nutri.2026.100004 · Cited by 2
Benefits of testosterone replacement
Hackett, G. I. (2013) · Trends in Urology & Men s Health · doi:10.1002/tre.342 · Cited by 2
Towe, M. M., Yafi, F. A., & Yafi, N. R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816665-9.00001-9 · Cited by 2
Panimolle, F., & Radicioni, A. F. (2017) · Frontiers in diabetes · doi:10.1159/000454742 · Cited by 2
Mel'nichenko, G. A., Shestakova, M. V., Rozhivanov, R. V., Терехова, А. Л., Zilov, A. V., Ladygina, D. O., & Курбатов, Д. Г. (2016) · Diabetes Mellitus · doi:10.14341/7884 · Cited by 2
Chodari, L., Pourheydar, B., Dariushnejad, H., Jamshidi, S., Khalaji, N., & Ghorbanzadeh, V. (2021) · Brazilian Archives of Biology and Technology · doi:10.1590/1678-4324-2021200037 · Cited by 2
Androgen Replacement Therapy in Hypogonadal Men
Čeponis, J., Swerdloff, R. S., & Wang, C. (2017) · Springer eBooks · doi:10.1007/978-3-319-53298-1_18 · Cited by 2
Segundo Consenso Argentino sobre patologías endocrinológicas
Pusiol, E. (2007) · Revista Argentina de Endocrinología y Metabolismo · Cited by 2
Late-onset hypogonadism or ADAM: treatment
Martits, A., Costa, E., Nardi, A., Nardozza, A., Facio, F., Faria, G., & Bernardo, W. (2014) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.60.05.005 · Cited by 2
Efficacy and safety of rosuvastatin in late-onset hypogonadism patients with dyslipidaemia
Kangwanvanich, S., & Permpongkosol, S. (2013) · Andrologia · doi:10.1111/and.12099 · Cited by 2
Testosterone: clinical relevance in ageing men
Huupponen, R., Huhtaniemi, I. T., & Lehtonen, A. (2009) · Reviews in Clinical Gerontology · doi:10.1017/s0959259809990372 · Cited by 2
Metabolic risk factors as a connecting link for men's health issues
Мамедов, М. Н. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.01.003 · Cited by 2
Androgens and cardiac diseases
Bianchi, V. E., & Mezzani, A. (2013) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2013.5232 · Cited by 2
Barkabi-Zanjani, S., Bavil, F. M., MOHAMMADI, M., CHODADI, L., Abbasi, M. M., MOHAMMADZAEH, M., Nazemi, S., & Shahabi, P. (2015) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/831 · Cited by 2
Effect of Methyltrienolone on the Metabolic Disorders in Rat Model of Alloxan-Induced Diabetes
Didebulidze, N., Kandelaki, S., Kakabadze, M., Kordzaia, S., Kordzaia, D., Relat, J. M., & Padillo, J. (2017) · European Scientific Journal ESJ · doi:10.19044/esj.2017.v13n15p22 · Cited by 2
(2015) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000162 · Cited by 2
Snyder, P. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-4907-4.00015-2 · Cited by 2
Rice, D., Roszler, J., & Farrell, J. A. B. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-208-7_14 · Cited by 2
Demirci, İ., Haymana, C., Demir, O., Akın, O., Meriç, C., Aydoğdu, A., & Sönmez, A. (2021) · Gulhane Medical Journal · doi:10.4274/gulhane.galenos.2021.96268 · Cited by 2
Elbardisi, H., & Majzoub, A. A. (2017) · Springer eBooks · doi:10.1007/978-3-319-56547-7_9 · Cited by 2
Russell, A., Ecclestone, H., & Kavia, R. (2014) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738014528687 · Cited by 2
The Aging Male and Late-Onset Hypogonadism
Rolf, C., Zitzmann, M., & Nieschlag, E. (2010) · Springer eBooks · doi:10.1007/978-3-540-78355-8_14 · Cited by 2
Androgen deficiency in the male
Mitchell, G. C., & Hellstrom, W. J. G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511997761.010 · Cited by 2
Almihy, N., Eissa, E. A., Amer, E., & Elassal, M. (2015) · Benha Medical Journal · doi:10.4103/1110-208x.170556 · Cited by 2
Roelfsema, F., Yang, R. J., & Veldhuis, J. D. (2018) · Journal of the Endocrine Society · doi:10.1210/js.2018-00141 · Cited by 2
Novel Approaches in the Management of Klinefelter Syndrome
Arshad, M. A., Yamani, M. M. A. O., Elbardisi, H., & Majzoub, A. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-32300-4_24 · Cited by 2
Snyder, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00015-9 · Cited by 2
Gildner, T. E. (2018) · Scholars' Bank (University of Oregon) · Cited by 2
Abonizio, I. T., Dourado, S. R. C., Sousa, T. C., Ricardo, M. L. S., Carmona, W. R., & Mendes, L. D. O. (2022) · Research Society and Development · doi:10.33448/rsd-v11i7.29772 · Cited by 1
Abichandani, V. K., & Kalhan, A. (2023) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_cdrp_20_22 · Cited by 1
Male Hypogonadism: The Korean Society of Men's Health and Aging Position Statement
Ahn, S. T., Kim, Y., Yu, S. H., & Chung, Y. (2025) · The World Journal of Men s Health · doi:10.5534/wjmh.240266 · Cited by 1
Impact of Testosterone Deficiency and Testosterone Therapy on Men’s Health
Traish, A. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-89650-7_13 · Cited by 1
The association of plasma testosterone level and progression of diabetic nephropathy in male
Tang, K., Du, C., Zhou, W., & Jing, Y. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02073-1 · Cited by 1
Liao, C., Hung, C.-L., Lee, J.-D., Hsu, Y., Lin, C.-Y., Shih, Y.-L., & Tsai, S.-H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1793890 · Cited by 1
Benefits and Risks of Testosterone Therapy in Men With Testosterone Deficiency
Traish, A. M., & Morgentaler, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813197-8.00018-x · Cited by 2
Male hypogonadism in patients on maintenance hemodiafiltration: prevalence and therapeutic effect
Carvalho, M. S., Torres, R. C., Toniasso, I. M., Magalhäes, A. O., Borges, C. M., Rocha, É. P. D. [., Kojima, C. A., & Elias, R. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1744953 · Cited by 1
Owiredua, C., Flink, I., Evans, B., & Boersma, K. (2026) · PAIN Reports · doi:10.1097/pr9.0000000000001416 · Cited by 1
Seneszenz und Altershypogonadismus
Rolf, C., Zitzmann, M., & Nieschlag, E. (2009) · Springer eBooks · doi:10.1007/978-3-540-92963-5_14 · Cited by 1
Endogenous Sex Hormones and Risk of Type 2 Diabetes Mellitus in Men and Women
Golden, S. H. (2010) · Principles of Gender-Specific Medicine · doi:10.1016/b978-0-12-374271-1.00056-3 · Cited by 1
Traitement androgénique des hypoandrismes masculins
Kuhn, J., & Prévost, G. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.06.021 · Cited by 1
The clinical importance of testosterone in men with type 2 diabetes
Hackett, G. I. (2010) · Trends in Urology & Men s Health · doi:10.1002/tre.159 · Cited by 1
‘Every obese male with type 2 diabetes should be screened for hypogonadism’
Jones, T. H., Quinton, R., & Ullah, A. (2011) · Practical Diabetes · doi:10.1002/pdi.1544 · Cited by 1
Self-citationCan the administration of testosterone to men with late-onset hypogonadism be discontinued?
Gooren, L. J. (2008) · Journal of Men s Health · doi:10.1016/j.jomh.2008.09.005 · Cited by 1
Testosterone Treatment Improves Insulin Resistance in Japanese Male Metabolic Syndrome
Ueshiba, H. (2013) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000116 · Cited by 1
Peptides, Sex, Diabetes, and the Kidney
Manigrasso, M. B., & Maric‐Bilkan, C. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-385095-9.00202-5 · Cited by 1
Krause, M. (2016) · Springer eBooks · doi:10.1007/978-3-662-48849-2_8 · Cited by 1
The Efficacy of Testosterone Ointment on Insulin Resistance in Men with Metabolic Syndrome
Ueshiba, H. (2017) · Journal of Metabolic Syndrome · doi:10.4172/2167-0943.1000225 · Cited by 1
Are Androgens Valuable in Management of Diabetes?
Kakabadze, M. (2017) · Current Research in Diabetes & Obesity Journal · doi:10.19080/crdoj.2017.02.555598 · Cited by 3
Rajandram, R., Koong, J. K., Quek, K. F., Lee, E. G., Razack, A. H. A., & Kuppusamy, S. (2022) · Clinical Endocrinology · doi:10.1111/cen.14682 · Cited by 1
Gandhi, R., Kumar, P. R., Pattanaik, S. R., & Sahoo, D. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_39_22 · Cited by 1
Shang, T., Zhang, J., Ma, H., Zou, S., Ren, Q., & Ren, Q. (2024) · Translational Andrology and Urology · doi:10.21037/tau-24-121 · Cited by 1
Association Between Type 2 Diabetes and Hypogonadism in India: An Observational Study
Unnikrishnan, A., Saboo, B., Majumdar, A., Saraogi, R. K., Sundar, S., Mahadevan, S., Ramakrishnan, A., Basu, I., Dutta, D., Bhattacharya, A. D., et al. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_262_23 · Cited by 1
Wang, C., Nieschlag, E., Swerdloff, R. S., Behre, H. M., Hellstrom, W. J. G., Gooren, L. J., Morales, Á., Kaufmann, J. M., Legros, J.-J., Lunenfeld, B., et al. (2010) · Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) · Cited by 1
Álvarez, A. Á., Falcón, M., Suárez, R. M. G., Amador, P., Calzado, M. C. A., Alonso, E. D., Puertas, A. C., Leyva, S. S., & Acosta, J. R. (2015) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Hormonersatzbehandlung in der Andropause – Nutzen und Risiken
Nigro, N., Christ‐Crain, M., & Meier, C. (2014) · Therapeutische Umschau · doi:10.1024/0040-5930/a000506 · Cited by 1
Metabolic syndrome in men with sexual dysfunction
Talukder, S. K., Afsana, F., & Khan, S. J. (2010) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2010.07.001 · Cited by 1
Androgens, visceral obesity and the risks for cardiovascular disease and diabetes mellitus
Gooren, L. J. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.02.001 · Cited by 1
Roles of Testosterone in Men with Type 2 Diabetes: A Review
Thanh, T. N., & Luu, P. D. (2014) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-319-11776-8_68 · Cited by 1
Cardiometabolic effects of testosterone in older men
Hackett, G. I. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000050 · Cited by 1
Adjunct Management of Male Hypogonadism
Bach, P. V., Najari, B. B., & Kashanian, J. A. (2016) · Current Sexual Health Reports · doi:10.1007/s11930-016-0089-7 · Cited by 1
Hypogonadism in Male Sexual Dysfunction
Stoian, D. L., Mozos, I. M., Craina, M. L., Paul, C., Velea, I. P., Schiller, A., & Crăciunescu, M. (2017) · InTech eBooks · doi:10.5772/intechopen.69107 · Cited by 1
Özderya, A. (2017) · Southern Clinics of Istanbul Eurasia · doi:10.14744/scie.2017.26043 · Cited by 1
Tiwari, A., & Srivastava, A. (2016) · Journal of Evidence Based Medicine and Healthcare · doi:10.18410/jebmh/2016/975 · Cited by 1
Androgen Therapy in Male Patients Suffering from Type 2 Diabetes: A Review of Benefits and Risks
Hassanabad, M. F., & Fatehi, M. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180731125724 · Cited by 1
Erectile dysfunction in type 2 diabetics: Does it need more attention?
Chakraborty, J., Chakraborty, S., & Chakraborty, R. (2018) · Journal of integrative nephrology and andrology · doi:10.4103/jina.jina_32_17 · Cited by 1
Androgen Support and Erectile Function in Men with Diabetes Mellitus Type 2 and Obesity
Luchytskyi, V. Y. (2018) · Health of Man · doi:10.30841/2307-5090.4.2018.171746 · Cited by 1
AL-Diwan, N. M. A.-A. M. A. (2014) · Journal of education for pure science. · Cited by 1
Primary and Preventative Care for Transgender Patients
Wolf-Gould, C., & Wolf-Gould, C. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-49642-1.00012-0 · Cited by 1
Age-Related Testosterone Deficiency Merits Treatment
Traish, A. M. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2020.0019 · Cited by 2
Review of literature: Etiology of obesity, risk factors, and the role of genetics
Abdullah, R. A. (2022) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2022.21.2.0443 · Cited by 1
Sadeghzadeh‐Bazargan, A., Roohaninasab, M., Seirafianpour, F., Shemshadi, M., Mohammadi, A., Mozafarpoor, S., & Goodarzi, A. (2022) · Surgical & Cosmetic Dermatology · doi:10.5935/scd1984-8773.2022140098 · Cited by 1
Re: The treatment of late-onset hypogonadism
Cangüven, Ö. (2014) · Urology Research and Practice · doi:10.5152/tud.2014.9513569 · Cited by 1
Hackett, G. I. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch13 · Cited by 1
Testosterone replacement therapy
Surampudi, V., & Swerdloff, R. S. (2015) · Cardiovascular Endocrinology · doi:10.1097/xce.0000000000000058 · Cited by 1
Hypogonadism and diabetes mellitus - Implications for cardiovascular risk
Madhu, S. (2017) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-017-0573-2 · Cited by 1
Willemse, P.-P. M., Burggraaf, J., Hamdy, N. A. T., & Osanto, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.567 · Cited by 1
The interrelationship of sex steroid levels, body composition and bone characteristics in men
Lapauw, B. (2009) · Ghent University Academic Bibliography (Ghent University)
Ishizuka, T., Kajita, K., Fujioka, K., Hanamoto, T., Ikeda, T., Mori, I., Yamauchi, M., Okada, H., Usui, T., Takahashi, N. K., et al. (2011) · InTech eBooks · doi:10.5772/22973
Late onset hypogonadism in males - think of it - act on it
Jackson, G. (2012) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2011.02865.x
Modulación metabólica de la oleoil estrona en ratas con sobrepeso
Romero, R., & del Mar, M. (2013) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Hypoandrogenismus und sexuelle Dysfunktion - Parameter oder Komorbidität des metabolischen Syndroms?
Abrahamian, H. (2008) · Journal für Kardiologie (Krause & Pachernegg GmbH)
The Effect of Testosterone on Metabolic Syndrome and Type 2 Diabetes
Quammen, A. (2010) · CommonKnowledge Research Repository (Pacific University Oregon)
Khan, M. A., Potdar, N., & Konje, J. C. (2021) · Assisted Reproduction Techniques · doi:10.1002/9781119622215.ch12
Aktuelle Aspekte: Altershypogonadismus und das metabolische Syndrom des Mannes
Zitzmann, M. (2008) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Androgen Decline in the Aging Male: Making Sense of the “Male Menopause”
Shoskes, D. A. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-900-6_9
Figueiredo, P. R. L., Martins, M. R. A., Montenegro, R. M., Albano, M. F., & Montenegro, R. M. (2009) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302009000800018
Déficit androgénico y síndrome metabólico
Hernández, J. J. C. (2007) · Revista Internacional de Andrología · doi:10.1016/s1698-031x(07)74065-7
Coronary Artery Disease in Men: The Role of Sex Hormones
Channer, K. S. (2006) · Future Cardiology · doi:10.2217/14796678.2.3.247
Self-citationHypoandrogen–metabolic (HAM) syndrome: an important men's health issue
Gould, D. C. (2007) · The Journal of Men s Health and Gender · doi:10.1016/j.jmhg.2007.03.007
Schubert, M. (2015) · Info Diabetologie · doi:10.1007/s15034-015-0516-2
Case Report: Treatment of Androgen Deficiency in the Aging Male
Hernandez, A., & Baum, N. H. (2008) · Postgraduate Medicine · doi:10.3810/pgm.2008.11.1941
Wang, C., Nieschlag, E., RONALD, S. S., Behre, H. M., WAYNE, J. H., LOUIS, J. G., JEAN, M. K., Legros, J., Lunenfeld, B., Morales, Á., et al. (2010) · Obesity and metabolism · doi:10.14341/2071-8713-5211
Buscarini, M., & Cardi, A. (2010) · International Urology and Nephrology · doi:10.1007/s11255-010-9717-8
RetractedDiabesity: aims of treatment and the multidisciplinary practice team
Rajeswaran, C., Bissell, J., Bachuwar, R., & Srinivasan, B. T. (2011) · Practice Nursing · doi:10.12968/pnur.2011.22.6.315
Therapeutic Potential of Testosterone Gels
Lunenfeld, B., & Oettel, M. (2009) · Aging Health · doi:10.2217/ahe.09.6
Farrell, J. A. B., Deshmukh, A., & Baghaie, A. A. (2010) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.09.59
Metadata
- Authors
- Kapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H.
- Affiliations
- Barnsley Hospital NHS Foundation Trust (GB)
- National Health Service (GB)
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-06
- Volume
- 154
- Issue
- 6
- Pages
- 899-906
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2142908894
- Cited by
- 791
- References
- 45
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 13 · 2023: 23 · 2022: 27 · 2021: 34 · 2020: 27 · 2019: 32 · 2018: 38 · 2017: 39 · 2016: 38 · 2015: 55 · 2014: 61 · 2013: 55 · 2012: 43
- FWCI
- 36.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- testosterone replacement therapy, hypogonadism, type 2 diabetes, insulin resistance, glycemic control, visceral fat, hypercholesterolemia, dyslipidemia, HbA1c, waist circumference, cardiovascular risk
- MeSH terms
- Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Humans, Hypercholesterolemia, Hypogonadism, Insulin Resistance, Male, Middle Aged, Testosterone, Cross-Over Studies, Hormone Replacement Therapy, Abdominal Fat
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
